AstraZeneca presents positive data from NIAGARA phase III trial of Imfinzi in combo with neoadjuvant chemotherapy in ...
Results from a post-hoc exploratory subgroup analysis from the NIAGARA phase III trial showed AstraZeneca’s Imfinzi (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free survival ( …